Severe acute respiratory syndrome (SARS) was once a global epidemic. Protheragen leads the way in SARS diagnostic development. Leveraging our vast expertise in in vitro diagnostic (IVD) kit and device development, we are dedicated to enhancing precise and prompt diagnosis of SARS for better therapeutic outcomes and public health.

Overview of Severe Acute Respiratory Syndrome

Severe acute respiratory syndrome or SARS is a viral illness of the human respiratory system caused by the SARS-CoV-1 virus. The disease first appeared in 2002 and caused an epidemic through of large geographical areas. SARS-CoV-1 virus is passed on via respiratory droplets and contact through contaminated surfaces. It causes symptoms including fever, coughing, myalgia and pneumonia. The SARS outbreak highlighted the urgent need to develop rapid diagnostic tools.

Fig. 1 Human antibody responses to SARS-CoV-1 and SARS-CoV-2 infection. (Wang, Ruoke, et al., 2023)

Diagnostic Biomarkers for Severe Acute Respiratory Syndrome

It is important to accurately and quickly diagnose these diseases in the event that SARS arises in the epidemic containment phase. The presence of diagnostic biomarkers warrants the easy processes of differential diagnosis, tracking and even management of SARS infections.

IVD Development for Severe Acute Respiratory Syndrome

The creation of in vitro diagnostic (IVD) tools is highly important for the accurate and rapid identification of the SARS-CoV-1 virus. Such tools help the healthcare personnel to diagnose severe acute respiratory syndrome (SARS) in a quick and accurate manner which is important for the timely control of further infections and for starting the appropriate therapy. The strategies and approaches described below constitute the basis for the development of effective IVD solutions for SARS.

• Viral RNA Detection: PCR-based tests targeting specific regions of the SARS-CoV-1 genome enable the sensitive and specific identification of viral genetic material.
• Antibody Detection: Enzyme-linked immunosorbent assay (ELISA) is a widely used serological test technique that can be used to detect and quantify antibodies in samples.
• Antigen Detection: Lateral flow immunoassay (LFIA) and ELISA can quickly and specifically identify SARS-CoV-1 antigens in samples such as nasopharyngeal swabs.

Our Services

Protheragen prides itself at being one of the leading players in the market of IVD solutions and SARS diagnostic development services. We are focused on designing tools that assist in the early diagnosis and accurate detection of viral infections, such as antigen, antibody, and RNA assays/kits targeting SARS. With the help of sophisticated diagnostic equipment, we aim to make the diagnostic process as simple as possible and fully automated.

Featured IVD Development Services for SARS

IVD Product Development Services

Protheragen's services extend even further. We provide you with point-of-care testing (POCT) and companion diagnostic development services targeted towards enhancing the quick diagnosis and effective therapy for the SARS. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.